Rimantadine Hydrochloride Tablets

This product is an antiviral drug, mainly active against influenza A virus. It inhibits the proliferation of type A viruses in vitro, including H1N1, H2N2 and H3N2 subtypes isolated from humans. It has both preventive and therapeutic effects on animals infected with influenza A myxovirus. It may work early in the viral replication cycle by inhibiting the uncoating of viral particles in host cells. It does not suppress the immune response after exposure to influenza A virus. It has only a weak effect on other types of influenza viruses.

The main ingredient of this product is adamantidine hydrochloride. Chemical name: α-methyl-1-adamantanemethylamine hydrochloride. Chemical structure: Molecular formula: C12H21N·HCl Molecular weight: 215.76

This product is a yellow film-coated tablet.

This product is used to prevent infection caused by influenza A virus strains. This product can supplement the preventive effect of vaccination and can be used for children and adults. This product is especially recommended for individuals at high risk, such as the elderly, immunodeficient patients and chronic patients; as well as individuals with pancreatic duct obstruction and individuals who are contraindicated or impossible to be vaccinated.

Oral administration: 0.2 g per day for adults and children over 10 years old, which can be administered once or in 2 doses. The start and duration of preventive treatment depends on the type of contact. If you are in close contact with a patient with viral influenza, such as a member of the same family, you should start taking the drug within 24-48 hours and continue for 8-10 days. For seasonal prevention without close contact, you should start taking the drug once the pathogen is identified as influenza A virus. Preventive treatment should last for 4-6 weeks. For the elderly, the dose may be reduced to 0.1 g per day or administered in 2 doses because the renal clearance rate decreases with aging. For children aged 1 to 10 years, take 5 mg/Kg (not more than 150 mg) per day, once or in 2 doses.

1. Gastrointestinal reactions: nausea, vomiting, abdominal pain, loss of appetite, diarrhea. 2. Neurological disorders: nervousness, insomnia, poor concentration, dizziness, headache, gait disorders in the elderly. 3. Others: weakness, dry mouth. The above adverse reactions can disappear after continued medication.

It is contraindicated for patients who are allergic to adamantanes and those with severe liver impairment.

Precautions for children: The safety and effectiveness of this product for preventing influenza A in children and treating children's flu symptoms have not been established. For children under 1 year old, the preventive study of this product has not been completed. Therefore, there is currently a lack of detailed research data on the use of this product in children. Precautions for pregnancy and lactation: Experiments have shown that this product can have teratogenic and non-teratogenic effects on animals. Therefore, this product can only be considered for use during pregnancy if it can be proven that the benefits of taking this product outweigh the disadvantages for mother and child. In animal experiments, taking rimantadine during lactation in rats had a negative impact on young rats. Rimantadine is concentrated in rat milk in a dose-dependent manner: 2 to 3 hours after taking rimantadine, the concentration in rat milk is twice that in serum. Therefore, for lactating women, this product can only be considered for use if it can be proven that the benefits of taking this product outweigh the disadvantages for mother and child. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

The chronic effect of cimetidine on the metabolism of rimantadine is unknown. When normal healthy adults took a single dose of 100 mg of rimantadine and started taking cimetidine (300 mg four times daily) 1 hour later, the total apparent clearance of rimantadine after the single dose was reduced by 18% (compared with the total apparent clearance of rimantadine in subjects with the same conditions who did not take cimetidine). Paracetamol Several healthy volunteers took rimantadine (100 mg twice daily) for 13 days and paracetamol (650 mg four times daily) on day 11 for 8 days. The pharmacokinetics of rimantadine were evaluated on days 11 and 13, and it was found that the peak plasma concentration and AUC value of rimantadine were reduced by approximately 11% after taking it with paracetamol. Aspirin: 12 healthy volunteers took this product (100 mg, twice a day) for 13 days. On the 11th day, they started taking aspirin (650 mg, four times a day) for 8 days. The pharmacokinetics of rimantadine were evaluated on the 11th and 13th days. It was found that after taking it together with aspirin, the peak plasma concentration and AUC value of rimantadine decreased by about 10%.

Keep sealed.

0.1g

36 months

Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

• Founded in:

  1995-08-08

• Address:

  No. 333, Jiangnan Road, Hengdian, Dongyang City, Zhejiang Province

• Tax NO.:

  913307831475538495

• Registered Funds:

  108.75 million yuan

• Website:

  Log in to view

• Email:

  Log in to view